NexoBrid Den Europæiske Union - dansk - EMA (European Medicines Agency)

nexobrid

mediwound germany gmbh - proteolytic enzymes enriched in bromelain - debridering - præparater til behandling af sår og sår - nexobrid er indiceret til fjernelse af eschar hos voksne med dybe partielle og fuld tykkelse termiske forbrændinger.

Upstaza Den Europæiske Union - dansk - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - aminosyre-metabolisme, infødte fejl - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Elfabrio Den Europæiske Union - dansk - EMA (European Medicines Agency)

elfabrio

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry disease - andre alimentary tract and metabolism produkter, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

Pombiliti Den Europæiske Union - dansk - EMA (European Medicines Agency)

pombiliti

amicus therapeutics europe limited - cipaglucosidase alfa - glycogen opbevaring sygdom type ii - andre alimentary tract and metabolism produkter, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Enzepi Den Europæiske Union - dansk - EMA (European Medicines Agency)

enzepi

allergan pharmaceuticals international ltd - pancreas pulver - eksokrin pancreatisk insufficiens - fordøjelsesmidler, inkl. enzymer - pancreas enzym udskiftning behandling i eksokrine pancreas insufficiens cystisk fibrose eller andre vilkår (e. kronisk pancreatitis, post-pancreatectomy eller kræft i bugspytkirtlen). enzepi er angivet i spædbørn, børn, unge og voksne.

Xenpozyme Den Europæiske Union - dansk - EMA (European Medicines Agency)

xenpozyme

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - andre alimentary tract and metabolism produkter, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Hemgenix Den Europæiske Union - dansk - EMA (European Medicines Agency)

hemgenix

csl behring gmbh - etranacogene dezaparvovec - hæmofili b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Xermelo Den Europæiske Union - dansk - EMA (European Medicines Agency)

xermelo

serb sas - telotristat etiprat - carcinoid tumor; neuroendocrine tumors - andre fordøjelseskanaler og stofskifteprodukter - xermelo er indiceret til behandling af carcinoid syndrom diarré i kombination med somatostatinanalog (ssa) behandling hos voksne, som ikke er tilstrækkeligt kontrolleret ved ssa-terapi.

Lumykras Den Europæiske Union - dansk - EMA (European Medicines Agency)

lumykras

amgen europe bv - sotorasib - carcinom, ikke-småcellet lunge - antineoplastiske midler - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Oncaspar Den Europæiske Union - dansk - EMA (European Medicines Agency)

oncaspar

les laboratoires servier - pegaspargase - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - oncaspar er indiceret som en komponent i antineoplastisk kombinationsbehandling i akut lymfoblastisk leukæmi (all) hos pædiatriske patienter fra fødsel til 18 år og voksne patienter.